Expressing support for continued investment to complete the development of an HIV vaccine.

Bill: 117-hres-1506
Sponsor: full_name: Rep. Williams, Nikema [D-GA-5]
Introduced: 2022-12-01
Policy area: Health
Subjects: HIV/AIDS

Immunology and vaccination

Medical research

Research and development
Latest action: action_date: 2022-12-01
text: Referred to the House Committee on Energy and Commerce.

Summaries:
action_date: 2022-12-01
action_desc: Introduced in House
text: <p>This resolution expresses support for the domestic development of a vaccine for HIV.</p>

tv_txt: IV 117th CONGRESS 2d Session H. RES. 1506 IN THE HOUSE OF REPRESENTATIVES December 1, 2022 Ms. Williams of Georgia (for herself and Ms. Lee of California ) submitted the following resolution; which was referred to the Committee on Energy and Commerce RESOLUTION Expressing support for continued investment to complete the development of an HIV vaccine.

Whereas HIV affects the entire globe and exists in a variety of subtypes; Whereas, in 2019, the estimated number of new HIV infections in adults and adolescents was approximately 34,800, and the overall rate of new HIV infections was 12.6 cases per 100,000 people in the United States; Whereas, at the end of 2019, the estimated HIV prevalence rate for persons 13 years of age and older in the United States was 431.0 per 100,000 people; Whereas, as of 2019, Black Americans have a rate of HIV infection that is 8.1 times higher than that of White Americans; Whereas, in 2019, there were 6.0 cases of HIV per 100,000 people that progressed from HIV to AIDS in the United States; Whereas, at the end of 2019, the AIDS prevalence rate among adults and adolescents in the United States was estimated at 192.3 per 100,000 people; Whereas, each year, more than 12,000 people with AIDS die in the United States; Whereas the people diagnosed with HIV in 2018 in the United States will pay a combined estimated lifetime total of $13,700,000,000 in direct medical expenses; Whereas it is estimated that patients on antiretroviral therapy with access to discounted medication have lifetime medical costs averaging $420,285, which rises to an average of $1,079,999 for patients without such access, based on an estimated life expectancy of 37.31 years after diagnosis; Whereas, in fiscal year 2022 alone, United States Federal domestic discretionary funding for HIV/AIDS programs totaled $7,425,800,000; Whereas the United States has contributed a total of $23,170,000,000 since 2002 to the Global Fund to Fight AIDS, Tuberculosis and Malaria, a multilateral effort supported by a number of countries and nongovernmental organizations; Whereas alternatives for preventing HIV transmission, formerly limited to abstinence, education, circumcision, and condoms, now include HIV prevention medicines such as preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP); Whereas 3 HIV vaccines (BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, and BG505 MD39.3 gp151 CD4KO mRNA) are currently in National Institutes of Health-funded phase 1 trials; Whereas President Biden has pledged to develop and implement a comprehensive national HIV/AIDS strategy that will include a focus on reducing HIV incidence; and Whereas continued government investment toward a viable HIV vaccine has the potential to improve public health in the United States: Now, therefore, be it

That the House of Representatives strongly encourages domestic efforts in the public and private sectors to invest in and complete the development of a vaccine for HIV.